Dr. Matthew Galsky spoke with CURE about the KEYNOTE-B15 trial results and their potential impact on muscle-invasive bladder cancer care. At the 2026 ASCO Genitourinary Cancers Symposium, the ...
Signatera detects molecular residual disease in bladder cancer by identifying tumor DNA fragments in the bloodstream, even when not visible on scans. The IMvigor010 trial showed that Signatera-guided ...
For years, Susan Johnstone, 53, lived with an embarrassing problem that threatened to take away the activity she loved most: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results